Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00083031
Status:
COMPLETED
Last Update Posted:
2019-05-21
First Post:
2004-05-14
Brief Title:
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
Metronomic Chemotherapy With Bevacizumab for Advanced Breast Cancer
Status:
COMPLETED
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This randomized phase II trial is studying metronomic low-dose cyclophosphamide and methotrexate to see how well they work compared to metronomic low-dose cyclophosphamide methotrexate and bevacizumab in treating women with metastatic breast cancer
Detailed Description:
This study uses an investigational drug called Bevacizumab Investigational means that this drug is not approved by the Federal Drug Administration and is still being studied Bevacizumab is the common name for the commercial drug Avastin The Bevacizumab used in this trial however is for use in research studies only and may be made at locations different from those where Avastin is made Although some differences may exist bevacizumab for research use and the commercial drug Avastin are manufactured by a similar process meet similar standards for final product testing and are expected to be very similar in safety and effectiveness
The purpose of this study is to find out what effects good and bad low-dose continuous chemotherapy referred to as metronomic chemotherapy using drugs Cytoxan also called cyclophosphamide and methotrexate CM with or without bevacizumab
The purpose of this study is to find out what effects good and bad low-dose continuous chemotherapy referred to as metronomic chemotherapy using drugs Cytoxan also called cyclophosphamide and methotrexate CM with or without bevacizumab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA006516 | NIH | None | httpsreporternihgovquickSearchP30CA006516 |
| P50CA089393 | NIH | None | None |